research: audit 2026 biotech roster and evidence boundaries

2026-10-31 20:47:46 +08:00
parent cb803662c3
commit f3d83901a1
5 changed files with 798 additions and 27 deletions
@@ -184,7 +184,7 @@ async function main() {
  const research = await researchResponse.json();
  assert.equal(research.companies.length, 1183);
  assert.equal(research.categories.length, 11);
-  assert.equal(research.evidence.length, 4268);
+  assert.equal(research.evidence.length, 4304);
  assert.equal(research.observations.length, 453);
  assert.equal((await request("/api/research/ai-companies", { method: "POST", headers })).status, 405);
  const researchPage = await request("/docs/other-research/ai-company-research/overview", { headers });
@@ -48,7 +48,7 @@ test("research revisions share the authentication database and preserve replay l
    assert.equal(consumeCode(config, "invalid"), "limited");
    const initial = readResearchSnapshot();
    assert.equal(initial.companies.length, 1183);
-    assert.equal(initial.evidence.length, 4268);
+    assert.equal(initial.evidence.length, 4304);
    assert.equal(initial.observations.length, 453);
    assert.deepEqual(initial.candidateBatches, seed.candidateBatches, "candidate gaps persist in the same database metadata");
    assert.deepEqual(initial.directoryRechecks, seed.directoryRechecks, "follow-up classifications persist without rewriting the discovery audit");
@@ -89,7 +89,7 @@ test("research validation rejects broken evidence and unsafe source links", () =
 test("reviews link explicit companies without turning global or excluded cases into companies", () => {
  const snapshot = structuredClone(seed) as ResearchSnapshot;
  assert.equal(snapshot.reviews.filter((r) => r.scope === "companies").length, 198);
-  assert.equal(snapshot.reviews.filter((r) => r.scope === "dataset").length, 89);
+  assert.equal(snapshot.reviews.filter((r) => r.scope === "dataset").length, 91);
  assert.equal(snapshot.reviews.filter((r) => r.scope === "excluded-candidate").length, 44);
  const review = snapshot.reviews.find((r) => r.id === "R4")!;
  assert.deepEqual(reviewCompanyIds(snapshot, review), ["AI007", "AI013", "AI021", "AI034"]);
@@ -430,7 +430,7 @@ test("unreconciled directory financials remain source reviews instead of income
  assert.ok(review.evidenceIds.includes("PH-TANA-DR"));
  assert.equal(reviewCompanyIds(snapshot, review).length, 0);
  assert.ok(!snapshot.observations.some((o) => o.evidence === "PH-TANA-DR"));
-  assert.equal(snapshot.candidateBatches!.flatMap((b) => b.records).filter((r) => r.status === "pending-year").length, 117);
+  assert.equal(snapshot.candidateBatches!.flatMap((b) => b.records).filter((r) => r.status === "pending-year").length, 121);
 });

 test("product pivots and founder histories do not become new company years or current revenue", () => {
@@ -1,5 +1,5 @@
 {
-  "version": "2026-10-31-tc26-manufacturing-1",
+  "version": "2026-10-31-tc26-biotech-1",
  "asOf": "2026-10-31",
  "scope": "全球公开资料研究：保留首批个案，并扩展核查2025—2026八个YC批次候选池；成立年份以官方公司页面字段为依据。",
  "limitations": [
@@ -91113,6 +91113,402 @@
      "kind": "官方/公司自述：2026制造工业组原始资料复核",
      "summary": "同域公司页Paris及2—10范围，OuijdaneQacami相关AI混凝土解释/StationF记录，无可读Founded。",
      "limitation": "加入孵化器/研究或媒体2025说法不替原始注册，原始法国登记尚未读；不将建筑资产价值/客户节约当ARR。"
+    },
+    {
+      "id": "TC26BIO-ALITHEA-1",
+      "companyId": null,
+      "title": "Alithea原始AI及实验平台",
+      "url": "https://alithea-bio.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "免疫肽组质谱/应用AI，HLACompass及结合预测白皮书。",
+      "limitation": "首页计数器零值不当真实样本零值；厂商预测准确性非独立临床验证，湿实验/样本处理/数据许可与软件净费分开。"
+    },
+    {
+      "id": "TC26BIO-ALITHEA-2",
+      "companyId": null,
+      "title": "Alithea原始公司年",
+      "url": "https://www.linkedin.com/company/alithea-bio",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报2019、Freiburg及11—50范围，免疫肽组/肿瘤免疫与数据库业务。",
+      "limitation": "自报非独立注册；不混瑞士AlitheaGenomics2020/AlitheaConsulting，获奖/客户药物价值不作ARR。"
+    },
+    {
+      "id": "TC26BIO-APERTUM-1",
+      "companyId": null,
+      "title": "Apertum原始临床前递送方案",
+      "url": "https://apertumneuro.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "非侵入刺激临时调节血脑屏障，官网展示啮齿/猪/非人灵长类信号及Cambridge地址，页脚ApertumNeuroInc。",
+      "limitation": "动物信号为厂商描述非人体获批疗效，区域646.1%相对对照不是人类成功率；疗程/器械/研发许可非纯软件ARR。"
+    },
+    {
+      "id": "TC26BIO-APERTUM-2",
+      "companyId": null,
+      "title": "Apertum原始公司缺年",
+      "url": "https://www.linkedin.com/company/apertum-neur",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司Paris、2—10范围，BBB递送研究与药企合作，无Founded。",
+      "limitation": "不混加拿大Speech2Health/Apertum、印度ApertumOnline等，二手2025未有原始成立补证；巴黎/Cambridge主体关系待核。"
+    },
+    {
+      "id": "TC26BIO-APERTUM-3",
+      "companyId": null,
+      "title": "Apertum所链Actipulse旧品牌关联",
+      "url": "https://actipulse.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "Apertum官网页脚直接链接Actipulse，后者官网展示临床神经调控/TMS业务。",
+      "limitation": "关联反链不证明两主体相同或新公司成立日；旧TMS收入/产品许可不继承Apertum新递送平台，AI核心未确认。"
+    },
+    {
+      "id": "TC26BIO-BIOTRILLION-1",
+      "companyId": null,
+      "title": "BioTrillion原始健康AI官网",
+      "url": "https://www.biotrillion.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "手机数据/图像AI与数字生物标记，面向日常健康观测。",
+      "limitation": "早筛/生命体征主张非独立监管/临床验证，未采人像/健康数据；市场浪费金额与自身ARR不同。"
+    },
+    {
+      "id": "TC26BIO-BIOTRILLION-2",
+      "companyId": null,
+      "title": "BioTrillion原始公司年与交付",
+      "url": "https://www.linkedin.com/company/biotrillion",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报2020、SanFrancisco及2—10范围，BioEngine4D/HealthySelfie与SDK。",
+      "limitation": "自报非独立注册，五种指标/10秒视频为厂商主张未独立测试；SDK集成、授权/消费订阅和实际合同分别核。"
+    },
+    {
+      "id": "TC26BIO-BRAIV-1",
+      "companyId": null,
+      "title": "BRAIV原域访问与团队缓存",
+      "url": "https://braiv.tech/team",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "原域及about/team直达无正文；原域搜索缓存列SindhuBanerjee/RabeesRafiq创始团队和AI神经科学方向。",
+      "limitation": "外壳不作关闭/零收入，AI处方/疗效主张未独立临床验证；药品收入/诊疗/前J&J项目不作软件ARR。"
+    },
+    {
+      "id": "TC26BIO-BRAIV-2",
+      "companyId": null,
+      "title": "BRAIV创始人原始2025问答",
+      "url": "https://www.chibus.com/people-and-careers/2025/5/14/building-a-braiv-startup-at-booth",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "SindhuBanerjee署名/问答2025-05-14称正在发展BRAIV、Booth创业资源与将于下一学年参加竞赛。",
+      "limitation": "文章日/入学年不替公司成立；旧创业1FG不继承，融资/竞赛计划不当实际收入。"
+    },
+    {
+      "id": "TC26BIO-BRAIV-3",
+      "companyId": null,
+      "title": "BRAIV原始大学项目描述",
+      "url": "https://polsky.uchicago.edu/2026/08/13/8-students-receive-2026-polsky-founders-fund-fellowships-to-work-on-their-ventures-full-time/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "Polsky大学项目将SindhuBRAIV描述为以真实世界结局和ML辅助精神科用药选择。",
+      "limitation": "项目支持非药物/产品获批或独立有效性验证；$150K竞赛/资助非订阅ARR，原始精确主体年份仍缺。"
+    },
+    {
+      "id": "TC26BIO-CHEMT-1",
+      "companyId": null,
+      "title": "ChemT原始细胞制造AI",
+      "url": "https://www.chemtbio.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "AI层面向CMC理解/调节细胞状态，帮助生物制品工艺开发。",
+      "limitation": "产量/质量提升为厂商描述非独立产品验证，降低药企成本不是自身收入，研发/化合物供应与软件经常净费分别核。"
+    },
+    {
+      "id": "TC26BIO-CHEMT-2",
+      "companyId": null,
+      "title": "ChemT原始公司年",
+      "url": "https://www.linkedin.com/company/chemt-biotechnology",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报2024、Singapore及2—10范围，小分子/AI生物制造。",
+      "limitation": "10关联账户非精确员工，公司自报非独立登记；invitro/invivo及5—10倍产量不能直接当人体效果或收入。"
+    },
+    {
+      "id": "TC26BIO-EFFERON-1",
+      "companyId": null,
+      "title": "Efferon原始血液吸附产品",
+      "url": "https://efferon.com",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "官网展示多模式血液吸附产品及适用研究/地区许可声明。",
+      "limitation": "治疗量、地区许可/CE为厂商主张未独立监管核对，不当临床疗效/实际订单；一次器械耗材收入非软件ARR。"
+    },
+    {
+      "id": "TC26BIO-EFFERON-2",
+      "companyId": null,
+      "title": "Efferon原始公司年",
+      "url": "https://www.linkedin.com/company/efferon",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报2016、Villach及51—200范围，单次血液灌流产品。",
+      "limitation": "自报非独立注册，旧/新治疗计数口径不同不硬加总；生物材料/临床支持与软件费分列，不以AI竞赛名单认定AI主营。"
+    },
+    {
+      "id": "TC26BIO-INFIUSS-1",
+      "companyId": null,
+      "title": "Infiuss原始临床模拟平台",
+      "url": "https://infiuss.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "历史/真实世界数据构建数字孪生，模拟试验，面向申办方/CRO/统计团队。",
+      "limitation": "虚拟患者量/试验成本减少非付费数或自身收入；模拟不代替真实临床验证，未上传患者资料或运行医学推演。"
+    },
+    {
+      "id": "TC26BIO-INFIUSS-2",
+      "companyId": null,
+      "title": "Infiuss原始公司年",
+      "url": "https://www.linkedin.com/company/infiuss",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报2021、Buffalo及11—50范围，MelissaBime等与试验软件相符。",
+      "limitation": "公司自报非独立登记，旧临床研究服务/项目预算与软件订阅净费分别核，机构合作Logo不等财务审计。"
+    },
+    {
+      "id": "TC26BIO-INTERO-1",
+      "companyId": null,
+      "title": "Intero原始类器官交付",
+      "url": "https://www.interobiosystems.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "干细胞来源人肠类器官，用于临床前药物测试。",
+      "limitation": "类器官功能/可靠性为厂商主张未独立验证；实验模型/样本/检测服务与软件净费分开。"
+    },
+    {
+      "id": "TC26BIO-INTERO-2",
+      "companyId": null,
+      "title": "Intero原始公司年与研究资金",
+      "url": "https://www.linkedin.com/company/intero-biosystems",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报2024、Aurora及2—10范围，MadelineEiken等；NIHNCATS PhaseI SBIR35万美元自述。",
+      "limitation": "自述非独立登记，SBIR研究资金不是软件ARR；孵化机构/实验结果不自动AI核心或人体获批。"
+    },
+    {
+      "id": "TC26BIO-LUME-1",
+      "companyId": null,
+      "title": "Lume原始可穿戴激素产品",
+      "url": "https://www.lumehealth.io",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "原域跳根域，展示汗液/皮质醇节律可穿戴设备与等候入口。",
+      "limitation": "示例读数/健康建议非独立临床/传感精度验证，未录入数据；设备/耗材/咨询与软件订阅净费分开。"
+    },
+    {
+      "id": "TC26BIO-LUME-2",
+      "companyId": null,
+      "title": "Lume原始公司年和原型状态",
+      "url": "https://www.linkedin.com/company/lumehealth",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报2023、SanFrancisco及2—10范围；当前团队说可穿戴原型/下轮beta。",
+      "limitation": "自报非独立注册，新原型不重置旧公司年；旧雇主Apple专利/百万设备销量、10万资助均不作LumeARR。"
+    },
+    {
+      "id": "TC26BIO-MYOGENE-1",
+      "companyId": null,
+      "title": "MyoGene原始药研与融资",
+      "url": "https://www.myogenebio.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "MyoDys45—55开发及2024罕见病/孤儿药指定自述，2025投资142万美元。",
+      "limitation": "指定不是上市许可/已证明人体疗效；药物研发/许可/里程碑/融资与软件收入不同。"
+    },
+    {
+      "id": "TC26BIO-MYOGENE-2",
+      "companyId": null,
+      "title": "MyoGene原始范围前新闻沿革",
+      "url": "https://www.myogenebio.com/news",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "原域列2019SBIR/研究资助、2020创业和2024会议/加速项目，CourtneyYoung团队对应。",
+      "limitation": "不是精确注册年但已范围前经营；旧研究投入/非现金支持非ARR，AI核心未见原始依据。"
+    },
+    {
+      "id": "TC26BIO-NANOTRACE-1",
+      "companyId": null,
+      "title": "Nanotrace原始药物递送平台",
+      "url": "http://nanotrace.com",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "RNA识别/纳米粒递送抗癌药物，临床前研发方向。",
+      "limitation": "靶向/安全效果是厂商主张非人体证明，软件定义粒子是技术描述非软件订阅；临床前实验/药物许可与软件净费分开。"
+    },
+    {
+      "id": "TC26BIO-NANOTRACE-2",
+      "companyId": null,
+      "title": "Nanotrace原始公司与缺年",
+      "url": "https://www.linkedin.com/company/nanotrace",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司SanFrancisco、2—10范围，WillBriley/PaulWeiss/DavidSpector，部分AI设计/程序化粒子，无Founded。",
+      "limitation": "前大学研究年/前SequoiaGoogle履历和投资者资金不继承为公司成立/收入；实际法律主体及商业合同待核。"
+    },
+    {
+      "id": "TC26BIO-ONCO-1",
+      "companyId": null,
+      "title": "OncoRevive原始多组学检测",
+      "url": "https://www.oncorevive.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "结合纳米技术/AI分析血液标志物，面向癌症检测/监测。",
+      "limitation": "两小时/四倍便宜/20倍速度为厂商声明，未经独立临床/监管核验；试剂检测/设备费不全算软件ARR。"
+    },
+    {
+      "id": "TC26BIO-ONCO-2",
+      "companyId": null,
+      "title": "OncoRevive原始加速机构成立年",
+      "url": "https://jobs.techstars.com/companies/oncorevive",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "Techstars同域名录列foundedin2023、Melbourne及1—10范围、preseed。",
+      "limitation": "机构资料非独立登记/临床性能核验，2025加速不重置成立，行业患者数和融资不作自身收入。"
+    },
+    {
+      "id": "TC26BIO-ORAIN-1",
+      "companyId": null,
+      "title": "Orain原始生物标记软件",
+      "url": "https://www.orainbio.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "当前计算生物标记研究/药物开发、组织影像多组学；页脚OrainBioInc，About列原始支持机构。",
+      "limitation": "当前pricing直达工具不可读，不推金额；研究结果/患者分层主张非独立临床验证，湿实验/处理/分析服务与软件费分开。"
+    },
+    {
+      "id": "TC26BIO-ORAIN-2",
+      "companyId": null,
+      "title": "Orain原始机构成立缓存",
+      "url": "https://greaterwashingtonpartnership.com/wp-content/uploads/2026/03/Next-Level-Growth-Exchange-2026-Handbook.pdf",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "GreaterWashingtonPartnership原始2026项目手册搜索缓存列NaroaGimenezCamino、ORAIN、Established2023、WashingtonDC、同域和JEROAI。",
+      "limitation": "当前PDF404与可读索引分列，非实时公司登记；机构项目材料不当独立财务/技术审计。"
+    },
+    {
+      "id": "TC26BIO-ORAIN-3",
+      "companyId": null,
+      "title": "Orain原始公司同域身份",
+      "url": "https://www.linkedin.com/company/orainbio/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司NaroaGimenezCamino、WashingtonDC及2—10范围，生物信息/图像AI平台，当前Founded缺。",
+      "limitation": "公司页缺年与手册2023来源分列，顾问前AstraZeneca/孵化资助不是本公司营收，不混OrainCosmetics/OrainStudio。"
+    },
+    {
+      "id": "TC26BIO-ORGAN-1",
+      "companyId": null,
+      "title": "OrganNexus原始平台与访问边界",
+      "url": "https://organnexus.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "原www不可访问，根域描述维持器官结构、干预/多维测量/建模和未见药物反应预测，RidaAmjed/MadhooPatil。",
+      "limitation": "示例明确HELDOUT—NOTRUN及读数零值不当真实实验/疗效；无成立/注册/收费/合同，器官来源研究伦理与技术效果未独立核验，实验服务/数据与软件净费分开。"
+    },
+    {
+      "id": "TC26BIO-SIT-1",
+      "companyId": null,
+      "title": "SitSense原始器械与原型",
+      "url": "https://sit-sense.com",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "传感识别压力区域并按协议调节的医疗座椅，称已在Michigan多设施演示。",
+      "limitation": "原型/专利/研究为厂商主张非获批或独立临床效果，未连接设备；护理省工/医疗总成本不是自身软件收入。"
+    },
+    {
+      "id": "TC26BIO-SIT-2",
+      "companyId": null,
+      "title": "SitSense原始公司年",
+      "url": "https://www.linkedin.com/company/sit-sense",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报2025、EastLansing及2—10范围，TamaraBush/JustinScott等，征集临床伙伴测试新原型。",
+      "limitation": "自报非独立登记/临床验证，投资/竞赛支持75000美元非ARR，机器人控制/证据算法不证明AI学习模型。"
+    },
+    {
+      "id": "TC26BIO-STUFF-1",
+      "companyId": null,
+      "title": "StuffThatWorks原始网址外壳",
+      "url": "https://www.stuffthatworks.health/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "网页工具仅提示启用JavaScript，未获得应用正文。",
+      "limitation": "不当关闭/零收入，不登录或采集患者报告；数据量/社区人数不作付费用户。"
+    },
+    {
+      "id": "TC26BIO-STUFF-2",
+      "companyId": null,
+      "title": "StuffThatWorks原始公司年",
+      "url": "https://at.linkedin.com/company/stuffthatworks",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "原始公司页Gegründet2018及TelAviv，患者众包/机器学习，YaelElish等对应；canonical直达429。",
+      "limitation": "公司自报非独立登记，患者经验不替因果/临床有效性；旧Waze收入/融资与数据许可及软件净费分开，不混stw澳洲IT公司。"
+    },
+    {
+      "id": "TC26BIO-SUNNY-1",
+      "companyId": null,
+      "title": "Sunny原始经期产品",
+      "url": "https://sunnyperiod.com/",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "官网销售月经杯/导入器，列55原$产品并称USFDA510kcleared，有积压单发货更新。",
+      "limitation": "清除声明未独立监管核验，不当药品批准/AI证明；预售/积压单/赠品/商品货款非软件ARR，未下单。"
+    },
+    {
+      "id": "TC26BIO-SUNNY-2",
+      "companyId": null,
+      "title": "Sunny原始公司成立与主体",
+      "url": "https://www.linkedin.com/company/sunny-period",
+      "publishedAt": null,
+      "accessedAt": "2026-10-31",
+      "kind": "官方/公司自述：2026生物制药组原始资料复核",
+      "summary": "同域公司自报MenstrualMatesInc2019、Boston及2—10范围，CindyBelardo/DrewJarvis。",
+      "limitation": "自报非独立登记，品牌新推广或2026加速不重置旧年，资助/众筹不当收入，不混Sunny同名AI应用。"
    }
  ],
  "reviews": [
@@ -98752,6 +99148,64 @@
        "TC26MF-NIOBIA-5"
      ],
      "handling": "原带参数URL/根域/跳转及缓存/直达失败分列；MUI复用2025旧候选沿革而不新增主公司，新域/总部不重置年。Niobia安全政策分层、无独立认证/技术实测；具名162登记/39待登记（生物17/健康22），Nunatak空锚待核，全来源未完成。"
+    },
+    {
+      "id": "TC26BIO-R-REVENUE",
+      "type": "药研、实验、器械耗材与AI软件净费",
+      "company": "2026生物制药17项",
+      "scope": "dataset",
+      "summary": "免疫肽组/类器官/活体器官实验、药物/化合物/基因治疗研发、试剂/血液吸附/传感器/座椅/月经杯实物与软件净费分列。",
+      "evidenceIds": [
+        "TC26BIO-ALITHEA-1",
+        "TC26BIO-APERTUM-1",
+        "TC26BIO-BIOTRILLION-1",
+        "TC26BIO-BRAIV-1",
+        "TC26BIO-CHEMT-1",
+        "TC26BIO-EFFERON-1",
+        "TC26BIO-INFIUSS-1",
+        "TC26BIO-INTERO-1",
+        "TC26BIO-LUME-1",
+        "TC26BIO-MYOGENE-1",
+        "TC26BIO-NANOTRACE-1",
+        "TC26BIO-ONCO-1",
+        "TC26BIO-ORAIN-1",
+        "TC26BIO-ORGAN-1",
+        "TC26BIO-SIT-1",
+        "TC26BIO-STUFF-1",
+        "TC26BIO-SUNNY-1"
+      ],
+      "handling": "无收入观测新增。孤儿药/罕见病指定、监管许可自述不当已上市或疗效/收入证明；SBIR/资助/天使投资/客户节约/行业患者成本不作软件ARR。数据许可、按次实验/检测、任务研发里程碑与经常软件合同需分别核。"
+    },
+    {
+      "id": "TC26BIO-R-ROSTER",
+      "type": "2026生物17项成立与原始证据边界",
+      "company": "2026总入口具名201URL",
+      "scope": "dataset",
+      "summary": "12项有范围前公司/原业务线索，4项主体成立待核，SitSense公司2025但预设调位算法非AI证明。",
+      "evidenceIds": [
+        "TC26AG-INDEX",
+        "TC26BIO-ALITHEA-2",
+        "TC26BIO-APERTUM-2",
+        "TC26BIO-BIOTRILLION-2",
+        "TC26BIO-BRAIV-2",
+        "TC26BIO-CHEMT-2",
+        "TC26BIO-EFFERON-2",
+        "TC26BIO-INFIUSS-2",
+        "TC26BIO-INTERO-2",
+        "TC26BIO-LUME-2",
+        "TC26BIO-MYOGENE-2",
+        "TC26BIO-NANOTRACE-2",
+        "TC26BIO-ONCO-2",
+        "TC26BIO-ORAIN-2",
+        "TC26BIO-SIT-2",
+        "TC26BIO-STUFF-2",
+        "TC26BIO-SUNNY-2",
+        "TC26BIO-APERTUM-3",
+        "TC26BIO-BRAIV-3",
+        "TC26BIO-ORAIN-3",
+        "TC26BIO-ORGAN-1"
+      ],
+      "handling": "BRAIV精神科不混braiv.co配音及其估算，Apertum/Actipulse旧项目不自动继承年/收入；原www失败/根域可读、缓存/404/429分列。动物信号不当人体实证、OrganNexus NOTRUN/零值非真实预测结果；具名179登记/22待登记及Nunatak空锚待核，全部来源未完成。"
    }
  ],
  "coverage": {
@@ -110246,6 +110700,273 @@
          ]
        }
      ]
+    },
+    {
+      "id": "TC-2026-battlefield-biotech-1",
+      "sourceId": "S02",
+      "url": "https://techcrunch.com/2026/08/20/the-2026-startup-battlefield-200-is-here-see-who-made-the-cut/",
+      "accessedAt": "2026-10-31",
+      "scope": "2026生物制药17原网址逐项核对：12旧年/原业务暂范围外，Apertum/BRAIV/Nanotrace/OrganNexus4主体成立待核，SitSense2025但AI核心待证。无新增主公司/收入；具名179登记/22待登记。",
+      "complete": false,
+      "records": [
+        {
+          "id": "TC26-BIO-ALITHEA",
+          "name": "Alithea Biotechnology",
+          "url": "https://alithea-bio.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "同域公司2019暂范围外，AI免疫肽组/数据库与质谱实验服务分列，不混AlitheaGenomics。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-ALITHEA-1",
+            "TC26BIO-ALITHEA-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-APERTUM",
+          "name": "Apertum Neuroscience",
+          "url": "https://apertumneuro.com/",
+          "categoryId": "C10",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "pending-year",
+          "note": "ApertumNeuroInc/Actipulse反链与旧项目沿革待核，当前原始公司无Founded；非侵入递送装置的AI核心也未见证明。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-APERTUM-1",
+            "TC26BIO-APERTUM-2",
+            "TC26BIO-APERTUM-3"
+          ]
+        },
+        {
+          "id": "TC26-BIO-BIOTRILLION",
+          "name": "BioTrillion",
+          "url": "https://www.biotrillion.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "同域公司自报2020暂范围外，手机视觉生物标记SDK/远程监测归C07；医疗市场规模不作软件收入。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-BIOTRILLION-1",
+            "TC26BIO-BIOTRILLION-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-BRAIV",
+          "name": "BRAIV",
+          "url": "https://braiv.tech/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "unavailable",
+          "status": "pending-year",
+          "note": "原域无正文/原始团队缓存与创始人2025问答对应，但精确成立缺；不混braiv.co视频配音企业或其估算收入。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-BRAIV-1",
+            "TC26BIO-BRAIV-2",
+            "TC26BIO-BRAIV-3"
+          ]
+        },
+        {
+          "id": "TC26-BIO-CHEMT",
+          "name": "ChemT Biotechnology",
+          "url": "https://www.chemtbio.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "同域公司2024暂范围外，AI设计小分子/虚拟细胞优化生物制造；湿实验/化合物/工艺授权与软件费分开。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-CHEMT-1",
+            "TC26BIO-CHEMT-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-EFFERON",
+          "name": "Efferon",
+          "url": "https://efferon.com",
+          "categoryId": "C10",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "同域公司2016暂范围外，血液吸附器械/耗材，不由2026认证或美国市场进入重置年；AI核心未见证据。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-EFFERON-1",
+            "TC26BIO-EFFERON-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-INFIUSS",
+          "name": "Infiuss Health",
+          "url": "https://infiuss.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "原始公司2021暂范围外，当前临床数字孪生与旧试验管理交付分列，不由新AI平台重置成立。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-INFIUSS-1",
+            "TC26BIO-INFIUSS-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-INTERO",
+          "name": "Intero Biosystems",
+          "url": "https://www.interobiosystems.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "同域公司2024暂范围外，类器官/临床前实验平台不自动AI软件企业。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-INTERO-1",
+            "TC26BIO-INTERO-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-LUME",
+          "name": "Lume Health Technologies",
+          "url": "https://www.lumehealth.io",
+          "categoryId": "C10",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "同域公司2023暂范围外，激素传感硬件/分析，当前可穿戴原型与既有健康服务分列。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-LUME-1",
+            "TC26BIO-LUME-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-MYOGENE",
+          "name": "MyoGene Bio",
+          "url": "https://www.myogenebio.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "原始官网2019—2024已有研究/创业记录暂范围外，基因编辑药研不自动软件ARR。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-MYOGENE-1",
+            "TC26BIO-MYOGENE-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-NANOTRACE",
+          "name": "Nanotrace",
+          "url": "http://nanotrace.com",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "pending-year",
+          "note": "原始纳米粒/RNA递送及AI设计线索可读，但同域公司无Founded；不从域名或前研究年推成立。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-NANOTRACE-1",
+            "TC26BIO-NANOTRACE-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-ONCO",
+          "name": "OncoRevive",
+          "url": "https://www.oncorevive.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "Techstars原始名录2023暂范围外，AI多组学检测/试剂及仪器与软件净费分开。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-ONCO-1",
+            "TC26BIO-ONCO-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-ORAIN",
+          "name": "ORAIN Biotechnologies",
+          "url": "https://www.orainbio.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "原始项目机构手册缓存2023暂范围外，OrainBioInc/同域研究AI；2025/2026支持项目不重置成立。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-ORAIN-1",
+            "TC26BIO-ORAIN-2",
+            "TC26BIO-ORAIN-3"
+          ]
+        },
+        {
+          "id": "TC26-BIO-ORGAN",
+          "name": "OrganNexus",
+          "url": "https://www.organnexus.com/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "pending-year",
+          "note": "原www工具不可用而根域可读，RidaAmjed/MadhooPatil活体器官数据/模型平台，精确主体和成立缺，模拟页面非实测。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-ORGAN-1"
+          ]
+        },
+        {
+          "id": "TC26-BIO-SIT",
+          "name": "Sit Sense, Inc.",
+          "url": "https://sit-sense.com",
+          "categoryId": "C10",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "pending-ai",
+          "note": "公司自报2025，但座椅自动调位/预设算法的AI主营未证，暂候选；不将医学算法自动作机器学习。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-SIT-1",
+            "TC26BIO-SIT-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-STUFF",
+          "name": "StuffThatWorks",
+          "url": "https://www.stuffthatworks.health/",
+          "categoryId": "C07",
+          "kind": "company",
+          "profileStatus": "unavailable",
+          "status": "outside-cohort",
+          "note": "原始公司2018暂范围外，患者报告数据/AI研究平台，JS外壳与公司缓存分别记录。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-STUFF-1",
+            "TC26BIO-STUFF-2"
+          ]
+        },
+        {
+          "id": "TC26-BIO-SUNNY",
+          "name": "Sunny",
+          "url": "https://sunnyperiod.com/",
+          "categoryId": "C09",
+          "kind": "company",
+          "profileStatus": "readable",
+          "status": "outside-cohort",
+          "note": "同域公司MenstrualMatesInc自报2019暂范围外，月经杯/导入器实物销售，未见AI主营原始证据。",
+          "evidenceIds": [
+            "TC26AG-INDEX",
+            "TC26BIO-SUNNY-1",
+            "TC26BIO-SUNNY-2"
+          ]
+        }
+      ]
    }
  ],
  "directoryRechecks": [
@@ -1,5 +1,5 @@
 {
-  "sourceVersion": "2026-10-31-tc26-manufacturing-1",
+  "sourceVersion": "2026-10-31-tc26-biotech-1",
  "asOf": "2026-10-31",
  "metric": "platform-mrr-usd",
  "sampleUnit": "product-or-business",